Quick Answer: In 1964, a way to produce an antihemophilic factor was identified by Judith Graham Pool of Stanford University. This antihemophilic factor was approved for commercial use in 1971 in the United States and was called Cryoprecipitated AHF.
Detailed Answer: Scientists and doctors in the early 1900s had no way of storing blood, so hemophiliacs would usually need a transfusion provided by usually a family member. By 1926, a US Surgeon General’s Catalogue housed an entire section of information and instructions on how to use of blood transfusions to replace the missing clotting factors in a hemophiliac. Scientists then discovered that patients reacted promptly to the infusion of a plasma after they endured spontaneous bleeding. Fast forward to 1965, Judith Graham Pool discovered that precipitate left from thawing plasma was rich in factor VIII which when infused would control serious bleeding and could be stored by blood banks. Then in the 1970s, the ability to freeze dry factor VIII and factor IX became applicable. In the 1990s synthetic clotting factor was being produced. The first factor product approved by the FDA in 1992 was a factor VIII product. and in 1997, the FDA admitted approval for a factor IX product. Other synthetic drugs, one of which was desmopressin acetate, was used to treat von Willebrand disease mild-to-moderate hemophilia A.
Comments